BioTuesdays

Category - Markets

T2 Biosystems Logo
Markets

AGP ups T2 Biosystems PT to $1.65 from $1.10

Alliance Global Partners raised its price target for T2 Biosystems (NASDAQ:TTOO) to $1.65 from $1.10 after hosting an investor webcast with the company’s CEO and CFO. The stock closed at $1.34 on Oct. 30. “Our...

November 2, 2020
Strongbridge Biopharma Logo
Markets

HCW cuts Strongbridge Biopharma PT to $10 from $18

H.C. Wainwright reduced its price target for Strongbridge Biopharma (NASDAQ:SBBP) to $10 from $18, citing an analysis of the changing dynamics of the Cushing’s syndrome landscape because of competitor programs. The...

October 30, 2020
DURECT
Markets

Chardan starts DURECT at buy; PT $7

Chardan Capital Markets launched coverage of DURECT (NASDAQ:DRRX) with a “buy” rating and price target of $7. The stock closed at $1.76 on Oct. 29. “We expect that DURECT’s lead pipeline asset, DUR-928, will...

October 30, 2020
Aspira-Women's-Health-Logo
Markets

William Blair starts Aspira Women’s Health at OP

William Blair launched coverage of Aspira Women’s Health (NASDAQ:AWH) with an “outperform” rating. The stock closed at $3.63 on Oct. 29. The company’s current product line, the OVA family, is used for presurgical pelvic...

October 30, 2020
DermTech-Logo
Markets

William Blair starts DermTech at OP

William Blair initiated coverage of DermTech (NASDAQ:DMTK) with an “outperform” rating. The stock closed at $11.75 on Oct. 29. Analyst Brian Weinstein writes that DermTech is focused on driving adoption of its non...

October 30, 2020
Axcella Logo
Markets

Chardan starts Axcella Health at buy; PT $16

Chardan Capital Markets initiated coverage of Axcella Health (NASDAQ:AXLA) with a “buy” rating and $16 price target. The stock closed at $4.45 on Oct. 26 “We expect that Axcella’s pipeline of endogenous metabolic...

October 27, 2020
Catabasis Pharma
Markets

HCW cuts Catabasis Pharma to neutral; removes PT

H.C. Wainwright downgraded Catabasis Pharmaceuticals (NASDAQ:CATB) to “neutral” from “buy” and removed its price target after the company announced that the Phase 3 PolarisDMD trial testing edasalonexent in 131 patients...

October 27, 2020
Immunome-Logo
Markets

Ladenburg starts Immunome at buy; PT $28

Ladenburg Thalmann initiated coverage of Immunome (NASDAQ:IMNM) with a “buy” rating and price target of $28. The stock closed at $11.74 on Oct. 23. Immunome is using its Immunome Discovery Engine (IDE) platform to...

October 26, 2020
Athenex
Markets

SVB Leerink starts Athenex at OP; PT $22

SVB Leerink launched coverage of Athenex (NASDAQ:ATNX) with an “outperform” rating and $22 price target. The stock closed at $11.45 on Oct. 23. Analyst Jonathan Chang, Ph.D., writes that Athenex has leveraged its...

October 26, 2020